Biotalys and Novozymes announce successful Evoca™ feasibility study
October 24 2022 - 1:00AM
Biotalys and Novozymes announce successful Evoca™ feasibility
study
Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech)
company protecting crops and food with protein-based biocontrol
solutions, and Novozymes, a world leader in biotech solutions
including Ag biologicals, today announced the successful outcome of
the feasibility study for Evoca™*, Biotalys’ first proprietary
biocontrol product candidate. Novozymes obtained proof of concept
for a new manufacturing process that offers potential significant
cost of goods and scaling advantages, thereby broadening the
commercial potential of Evoca as a novel biofungicide.
“Thanks to its leading protein fermentation
expertise, Novozymes has been able to further increase the
efficiency of production for Evoca,” said Patrice Sellès,
the CEO of Biotalys. “We will now work on a deeper
partnership with Novozymes and explore strategic supply and
commercialization agreements for the future generation of Evoca
while continuing our ongoing internal development activities.”
Evoca is Biotalys’ first innovative
protein-based biofungicide developed on the company’s AGROBODY
Foundry™ platform. This technology platform allows Biotalys to
discover and develop novel biological food protection solutions
that combine high efficacy, consistency and safety, with new modes
of action to fight resistance. Evoca helps sustainably control
economically important fungal diseases such as Botrytis and powdery
mildew in fruits and vegetables. Demonstrating strong performance
across more than 600 independent and company-driven field and
greenhouse trials across multiple regions, pathogens and crops,
Evoca is expected to obtain approval by the U.S. Environmental
Protection Agency (EPA) in early 2023.
Since entering into a partnership in June 2022,
Novozymes has explored additional routes for the upscaling and
production of the bioactive protein of Evoca by using production
hosts additional to those currently used by Biotalys. Novozymes
uncovered new ways to scale production and efficiency that could
help Biotalys drive broader commercial reach for Evoca, both in the
preliminary U.S. and E.U. fruits and vegetables markets currently
in the commercialization plan, as well as in additional
geographies, crops and diseases. Subject to confirmation of
commercial scale-up, field trial performance and regulatory
procedures, these results may help reduce time to a commercially
attractive version of Evoca.
“The results of this feasibility study with
Biotalys will help pave the way for more cost-efficient,
sustainable solutions for growers around the world,” noted
Thomas Batchelor, Vice President, Agriculture
Marketing and Strategy of Novozymes. “Now one step closer
to large-scale production, Biotalys and Novozymes have successfully
collaborated to provide the industry and growers new ways to safely
control damaging pests and diseases and deliver our shared goal of
providing highly effective solutions so growers can sustainably
feed the world.”
Successfully achieving this key milestone, the
two companies are now entering into the next phase of their
partnership and will explore strategic supply and commercialization
agreements for the future generation of Evoca. Novozymes and
Biotalys will also explore an R&D collaboration beyond Evoca to
address the needs for effective and more sustainable protein-based
biocontrols in novel markets and indications through both
Novozymes’ solution portfolio and Biotalys’s pipeline of product
candidates.
* Evoca™: Pending Registration. This product is
not currently registered for sale or use in the United States, the
European Union, or elsewhere and is not being offered for sale.
About Biotalys
Biotalys is an Agricultural Technology (AgTech)
company protecting crops and food with proprietary protein-based
biocontrol solutions and aiming to provide alternatives to
conventional chemical pesticides for a more sustainable and safer
food supply. Based on its novel AGROBODY™ technology platform,
Biotalys is developing a strong and diverse pipeline of effective
product candidates with a favorable safety profile that aim to
address key crop pests and diseases across the whole value chain,
from soil to plate. Biotalys was founded in 2013 as a spin-off from
the VIB (Flanders Institute for Biotechnology) and is listed on
Euronext Brussels since July 2021. The company is based in the
biotech cluster in Ghent, Belgium. More information can be found on
www.biotalys.com.
For further information, please
contact
Toon Musschoot, Head of IR & CommunicationT:
+32 (0)9 274 54 00E: Toon.Musschoot@biotalys.com
About Novozymes
Novozymes is the world leader in biological
solutions. Together with customers, partners, and the global
community, we improve industrial performance while preserving the
planet's resources and helping build better lives. As the world's
largest provider of enzyme and microbial technologies, our
bioinnovation enables higher agricultural yields, low-temperature
washing, energy-efficient production, renewable fuel, and many
other benefits that we rely on today and in the future. We call it
Rethink Tomorrow. www.novozymes.com
NASDAQ OMX: NZYM-B • 6,500 employees • DKK 15
billion turnover • 30+ industries • 700+ products
Media Relations
Lina Danstrup | Head of Media Relations | Phone:
+45 30 77 05 52 | lind@novozymes.com
Investor RelationsTobias Bjorklund
| Head of Investor Relations | Phone: +45 30 77 86 82
| tobb@novozymes.com
Important Notice
This announcement contains statements which are
"forward-looking statements" or could be considered as such. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the words ‘aim’, 'believe',
'estimate', 'anticipate', 'expect', 'intend', 'may', 'will',
'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans',
'target', 'seek', 'would' or 'should', and contain statements made
by the company regarding the intended results of its strategy. By
their nature, forward-looking statements involve risks and
uncertainties and readers are warned that none of these
forward-looking statements offers any guarantee of future
performance. The Biotalys actual results may differ materially from
those predicted by the forward-looking statements. Biotalys makes
no undertaking whatsoever to publish updates or adjustments to
these forward-looking statements, unless required to do so by
law.
- Biotalys en Novozymes partnership update persbericht - 24
oktober 2022_NL
- Biotalys and Novozymes partnership update press release - 24
October 2022_ENG
Biotalys (EU:BTLS)
Historical Stock Chart
From Apr 2024 to May 2024
Biotalys (EU:BTLS)
Historical Stock Chart
From May 2023 to May 2024